Key statistics
On Friday, Lisata Therapeutics Inc (0HS8:LSE) closed at 4.59, -5.20% below its 52-week high of 4.84, set on Jan 27, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 4.59 |
| Low | 4.59 |
| Bid | -- |
| Offer | -- |
| Previous close | 4.75 |
| Average volume | 4.01k |
|---|---|
| Shares outstanding | 8.82m |
| Free float | 7.09m |
| P/E (TTM) | -- |
| Market cap | 40.58m USD |
| EPS (TTM) | -2.13 USD |
Data delayed at least 20 minutes, as of Feb 06 2026 16:39 GMT.
More ▼
Announcements
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
More ▼
